Basis: FMP quote market capitalization / four-quarter operating cash flow. Source: stored company filings and market data; unavailable inputs remain N/A.
The Price/OCF ratio is N/A as of 2026-10-06T19:22:43.112Z.
Calculation as of: 2026-10-06T19:22:43.112Z.
Quote observation: 2026-10-06T19:11:02.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: e073f5428848077c7a0d0cc6d23bf3e17d592f54f36e36df4abd9dbcce493245
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PRICE/OCF RATIO
N/A
Mustang Bio, Inc.
Market Cap
$3.49M
Price/OCF Ratio
N/A
| NAME | MARKET CAP | PRICE/OCF RATIO |
|---|---|---|
| Mustang Bio, Inc. (MBIO) | $3.49M | N/A |
| Nexalin Technology, Inc. (NXL)vs › | $3.49M | N/A |
| Moolec Science S.A. (MLEC)vs › | $3.46M | N/A |
| Eocene Ltd. (EOCN)vs › | $3.64M | N/A |
| Cadrenal Therapeutics, Inc. Common Stock (CVKD)vs › | $3.64M | N/A |
| WORK Medical Technology Group Ltd. Class A (WOK)vs › | $3.65M | N/A |
| Paranovus Entertainment Technology Ltd. (PAVS)vs › | $3.32M | N/A |
| Evogene Ltd. (EVGN)vs › | $3.66M | N/A |
| Ernexa Therapeutics Inc. (ERNA)vs › | $3.69M | N/A |
| Aethlon Medical, Inc. (AEMD)vs › | $3.23M | N/A |
P/OCF Ratio
N/A
P/FCF Ratio
N/A
P/OCF measures market price relative to operating cash flow: market cap divided by TTM operating cash flow. OCF is cash from operations before capital expenditures, so it sits above free cash flow — P/OCF typically reads below P/FCF, with the widest gap for capex-heavy businesses.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
